CAJ | 학술논문

蒽环类药物包括阿霉素、表阿霉素、柔红霉素和阿克拉霉素等，广泛地用于治疗血液系统恶性肿瘤和实体肿瘤，如急性白血病、淋巴瘤、乳腺癌、胃癌、软组织肉瘤和卵巢癌等。蒽环类药物可以与其他化疗药物及分子靶向药物联合应用，以蒽环类药物为基础的联合治疗通常是一线治疗的标准方案。蒽环类药物的抗瘤谱广，抗瘤作用强，疗效确切，但是可以引起脱发、骨髓抑制和心脏毒性等毒副反应。针对骨髓抑制可采用造血刺激因子（G-CSF、EPO、TPO等）进行防治，而心脏毒性是蒽环类药物最严重的毒副反应。临床研究和实践观察均显示蒽环类药物导致的心脏毒性呈进展性和不可逆性，特别是初次使用蒽环类药物就可能造成心脏损伤，因此早期监测和积极预防蒽环类药物引起的心脏毒性显得尤为重要，已经引起临床上的高度重视，制定了蒽环类药物心脏毒性防治指南。本研究对目前蒽环类药物心脏毒性的防治药物进行综述。
은배류약물포괄아매소、표아매소、유홍매소화아극랍매소등，엄범지용우치료혈액계통악성종류화실체종류，여급성백혈병、림파류、유선암、위암、연조직육류화란소암등。은배류약물가이여기타화료약물급분자파향약물연합응용，이은배류약물위기출적연합치료통상시일선치료적표준방안。은배류약물적항류보엄，항류작용강，료효학절，단시가이인기탈발、골수억제화심장독성등독부반응。침대골수억제가채용조혈자격인자（G-CSF、EPO、TPO등）진행방치，이심장독성시은배류약물최엄중적독부반응。림상연구화실천관찰균현시은배류약물도치적심장독성정진전성화불가역성，특별시초차사용은배류약물취가능조성심장손상，인차조기감측화적겁예방은배류약물인기적심장독성현득우위중요，이경인기림상상적고도중시，제정료은배류약물심장독성방치지남。본연구대목전은배류약물심장독성적방치약물진행종술。
Anthracyclines, which include doxorubicin, epirubicin, daunorubicin, and aclarubicin, are widely used chemotherapeu-tic agents for treating hematologic and solid tumors, such as acute leukemia, lymphoma, breast cancer, gastric cancer, soft tissue sarco-mas, and ovarian cancer. Anthracyclines can be combined with other chemotherapeutics and molecular targeted drugs for cancer treat-ment. The combination of anthracyclines with other chemotherapeutic drugs is usually the standard of first-line treatment. Anthracy-clines are efficacious and potent agents with broad antitumor effects. However, these drugs may cause adverse reactions, such as hair loss, myelotoxicity, and cardiotoxicity. Hematopoietic stimulating factors, such as granulocyte colony-stimulating factor, erythropoietin, and thrombopoietin, can be used to control myelotoxicity. However, cardiotoxicity is the most serious anthracycline side effect. Clinical study results and practical observations indicate that the anthracycline cardiotoxicity is usually progressive and irreversible, especially after the first use of the drug, which may particularly cause heart damage. Therefore, the early detection and prevention of anthracy-cline-induced cardiotoxicity are important and have already gained considerable attention in clinical applications. Relevant experts from the China Society of Clinical Oncology and Hematology Branch of the Chinese Medical Association prepared the guidelines for the pre-vention and cure of anthracycline-induced cardiotoxicity in 2013. The authors reviewed the effective drugs currently used to prevent and cure anthracycline cardiotoxicity.